These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 7646591

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
    Fournier A, Oprisiu R, Hottelart C, Yverneau PH, Ghazali A, Atik A, Hedri H, Said S, Sechet A, Rasolombololona M, Abighanem O, Sarraj A, El Esper N, Moriniere P, Boudailliez B, Westeel PF, Achard JM, Pruna A.
    Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
    [Abstract] [Full Text] [Related]

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 4. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V, Torregrosa V.
    Nefrologia; 2008 Nov; 28 Suppl 3():67-78. PubMed ID: 19018742
    [Abstract] [Full Text] [Related]

  • 5. Bone turnover in rats treated with 1,25-dihydroxyvitamin D3, 25-hydroxyvitamin D3 or 24,25-dihydroxyvitamin D3.
    Mortensen BM, Gautvik KM, Gordeladze JO.
    Biosci Rep; 1993 Feb; 13(1):27-39. PubMed ID: 8392394
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Secondary hyperparathyroidism in osteomalacia.
    Thalassinos NC, Wicht S, Joplin GF.
    Br Med J; 1970 Jan 10; 1(5688):76-9. PubMed ID: 5411449
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol?
    Ghazali A, Fardellone P, Pruna A, Atik A, Achard JM, Oprisiu R, Brazier M, Remond A, Morinière P, Garabedian M, Eastwood J, Fournier A.
    Kidney Int; 1999 Jun 10; 55(6):2169-77. PubMed ID: 10354266
    [Abstract] [Full Text] [Related]

  • 16. Tumor-induced osteomalacia: pre- and postoperative biochemical findings.
    Leicht E, Biro G, Langer HJ.
    Horm Metab Res; 1990 Dec 10; 22(12):640-3. PubMed ID: 1963876
    [Abstract] [Full Text] [Related]

  • 17. Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1.
    Hannan FM, Athanasou NA, Teh J, Gibbons CL, Shine B, Thakker RV.
    Eur J Endocrinol; 2008 Feb 10; 158(2):265-71. PubMed ID: 18230836
    [Abstract] [Full Text] [Related]

  • 18. Parathyroid hormone suppression by 22-oxacalcitriol in the severe parathyroid hyperplasia.
    Funahashi H, Tanaka Y, Imai T, Wada M, Tsukamura K, Hayakawa Y, Matsuura N, Kikumori T, Oiwa M, Tominaga Y, Takagi H.
    J Endocrinol Invest; 1998 Jan 10; 21(1):43-7. PubMed ID: 9633022
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tumor-induced osteomalacia: clinical and basic studies.
    Shane E, Parisien M, Henderson JE, Dempster DW, Feldman F, Hardy MA, Tohme JF, Karaplis AC, Clemens TL.
    J Bone Miner Res; 1997 Sep 10; 12(9):1502-11. PubMed ID: 9286768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.